{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:20:57Z","timestamp":1790785257383,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10RR026917-01"],"award-info":[{"award-number":["S10RR026917-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U24CA264298"],"award-info":[{"award-number":["U24CA264298"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","award":["KAW 2023.0463"],"award-info":[{"award-number":["KAW 2023.0463"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014549","name":"Stanford Cancer Institute","doi-asserted-by":"publisher","award":["P30CA124435"],"award-info":[{"award-number":["P30CA124435"]}],"id":[{"id":"10.13039\/100014549","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.biopha.2026.119846","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T07:07:59Z","timestamp":1786950479000},"page":"119846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Tumor size limits macrophage activation and imaging response to CD47 blockade in osteosarcoma"],"prefix":"10.1016","volume":"203","author":[{"given":"Raheleh","family":"Roudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6854-1423","authenticated-orcid":false,"given":"Giovanni Marco","family":"Saladino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Vasyliv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3084-3300","authenticated-orcid":false,"given":"Laura","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3600-6375","authenticated-orcid":false,"given":"Jason","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8223-7233","authenticated-orcid":false,"given":"Wencke","family":"Reineking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Duwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Pribnow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike E.","family":"Daldrup-Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119846_bib1","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/cncr.34163","article-title":"Osteosarcoma: A Surveillance, Epidemiology, and End Results program-based analysis from 1975 to 2017","volume":"128","author":"Cole","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2026.119846_bib2","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jnci\/djae229","article-title":"Effect of chemotherapy and surgery timing on mortality in upper and lower extremity osteosarcoma","volume":"117","author":"Danese","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.biopha.2026.119846_bib3","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2147\/CMAR.S378264","article-title":"The combination of anlotinib and gemcitabine\/docetaxel in patients with metastatic osteosarcoma who have failed standard chemotherapy","volume":"14","author":"Wang","year":"2022","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.biopha.2026.119846_bib4","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1007\/s00262-021-02876-w","article-title":"Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial","volume":"70","author":"Boye","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2026.119846_bib5","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s43018-024-00749-6","article-title":"Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial","volume":"5","author":"Hegde","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.biopha.2026.119846_bib6","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00262-015-1731-3","article-title":"A phase I trial combining decitabine\/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma","volume":"64","author":"Krishnadas","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2026.119846_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006991","article-title":"Cell membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models","volume":"12","author":"Hu","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2026.119846_bib8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00262-025-04051-x","article-title":"Osteosarcoma cell-derived CCL2 facilitates lung metastasis via accumulation of tumor-associated macrophages","volume":"74","author":"Kondo","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2026.119846_bib9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3390\/cancers12020305","article-title":"Targeting CD47 as a novel immunotherapy for multiple myeloma","volume":"12","author":"Sun","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119846_bib10","article-title":"A novel blockade CD47 antibody with therapeutic potential for cancer","volume":"10","author":"Lin","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119846_bib11","doi-asserted-by":"crossref","first-page":"23662","DOI":"10.18632\/oncotarget.4282","article-title":"CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models","volume":"6","author":"Xu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119846_bib12","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2026.119846_bib13","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.3390\/cells13221862","article-title":"CD47 in osteosarcoma: Correlation with metastasis and macrophage-mediated phagocytosis","volume":"13","author":"Ko","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2026.119846_bib14","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-5797","article-title":"Abstract 5797: Impact of baseline tumor size on response to anti-CD47 immunotherapy in an osteosarcoma mouse model","volume":"85","author":"Roudi","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119846_bib15","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1158\/2326-6066.CIR-14-0187","article-title":"STAT3 signaling is required for optimal regression of large established tumors in mice treated with anti-OX40 and TGF\u03b2 receptor blockade","volume":"3","author":"Triplett","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biopha.2026.119846_bib16","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1073\/pnas.1918971117","article-title":"Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity","volume":"117","author":"Morrison","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2026.119846_bib17","doi-asserted-by":"crossref","first-page":"16902","DOI":"10.1038\/s41598-019-52913-z","article-title":"A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer","volume":"9","author":"Guisier","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119846_bib18","first-page":"1235","article-title":"First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced solid tumors","volume":"20","author":"Sikic","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2026.119846_bib19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00277-021-04734-2","article-title":"Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes","volume":"101","author":"Zeidan","year":"2022","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.biopha.2026.119846_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.3064","article-title":"Results of a first-in-human phase I study of SRF231, a fully human, high-affinity anti-CD47 antibody","volume":"38","author":"Patnaik","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119846_bib21","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1158\/1078-0432.CCR-18-0673","article-title":"Magnetic resonance imaging of tumor-associated macrophages: Clinical translation","volume":"24","author":"Aghighi","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119846_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41419-018-1285-3","article-title":"Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma","volume":"10","author":"Mohanty","year":"2019","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.biopha.2026.119846_bib23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s41747-024-00467-9","article-title":"Reproducibility and repeatability of quantitative T2 and T2* mapping of osteosarcomas in a mouse model","volume":"8","author":"Roudi","year":"2024","journal-title":"Eur. Radiol. Exp."},{"key":"10.1016\/j.biopha.2026.119846_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open sourcesoftware for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119846_bib25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/RLI.0000000000001030","article-title":"Novel Clinically Translatable Iron Oxide Nanoparticle for Monitoring Anti-CD47 Cancer Immunotherapy","volume":"59","author":"Roudi","year":"2023","journal-title":"Invest. Radiol."},{"key":"10.1016\/j.biopha.2026.119846_bib26","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.biopha.2026.119846_bib27","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/bioinformatics\/btab686","article-title":"FLINO: a new method for immunofluorescence bioimage normalization","volume":"38","author":"Graf","year":"2022","journal-title":"Bioinformatics"},{"key":"10.1016\/j.biopha.2026.119846_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005857","article-title":"CD47 expression is critical for CAR T-cell survival in vivo","volume":"11","author":"Beckett","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2026.119846_bib29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-024-07443-8","article-title":"Engineered CD47 protects T cells for enhanced antitumour immunity","volume":"630","author":"Yamada-Hunter","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119846_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206223","article-title":"Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments","volume":"13","author":"Yu","year":"2018","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119846_bib31","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/cac2.12420","article-title":"High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway","volume":"43","author":"Wen","year":"2023","journal-title":"Cancer Commun."},{"key":"10.1016\/j.biopha.2026.119846_bib32","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/CJI.0b013e318189f13c","article-title":"Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer","volume":"32","author":"Moo-Young","year":"2009","journal-title":"J. Immunother."},{"key":"10.1016\/j.biopha.2026.119846_bib33","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1158\/0008-5472.CAN-11-1094","article-title":"Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression","volume":"71","author":"Noman","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119846_bib34","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3109\/10428194.2012.726721","article-title":"Role of interleukin-10 in the regulation of tumorigenicity of a T cell lymphoma","volume":"54","author":"Hassuneh","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.biopha.2026.119846_bib35","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.seminoncol.2019.10.002","article-title":"Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors","volume":"46","author":"Hopkins","year":"2019","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.biopha.2026.119846_bib36","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-17-2386","article-title":"Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab","volume":"24","author":"Joseph","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119846_bib37","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s10147-020-01669-y","article-title":"Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer","volume":"25","author":"Suzuki","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119846_bib38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.21037\/tlcr-21-815","article-title":"Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy","volume":"11","author":"Uehara","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.biopha.2026.119846_bib39","doi-asserted-by":"crossref","first-page":"815","DOI":"10.21873\/anticanres.13180","article-title":"Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer","volume":"39","author":"Katsurada","year":"2019","journal-title":"Anticancer. Res."},{"key":"10.1016\/j.biopha.2026.119846_bib40","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1158\/1078-0432.CCR-16-1990","article-title":"Correlation between ferumoxytol uptake in tumor lesions by MRI and response to nanoliposomal irinotecan in patients with advanced solid tumors: A pilot study","volume":"23","author":"Ramanathan","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119846_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142665","article-title":"Imaging tumor necrosis with ferumoxytol","volume":"10","author":"Aghighi","year":"2015","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119846_bib42","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41598-020-58219-9","article-title":"Validation of MRI quantitative susceptibility mapping of superparamagnetic iron oxide nanoparticles for hyperthermia applications in live subjects","volume":"10","author":"Deh","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119846_bib43","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s11307-019-01409-3","article-title":"Ferumoxytol Does Not Impact Standardized Uptake Values on PET\/MR Scans","volume":"22","author":"Muehe","year":"2020","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.biopha.2026.119846_bib44","doi-asserted-by":"crossref","first-page":"7742","DOI":"10.1039\/D1RA08061J","article-title":"Magnetic resonance imaging of tumor-associated-macrophages (TAMs) with a nanoparticle contrast agent","volume":"12","author":"Zhou","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.biopha.2026.119846_bib45","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.actbio.2025.01.003","article-title":"A subtype specific probe for targeted magnetic resonance imaging of M2 tumor-associated macrophages in brain tumors","volume":"194","author":"Li","year":"2025","journal-title":"Acta Biomater."},{"key":"10.1016\/j.biopha.2026.119846_bib46","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1158\/1078-0432.CCR-18-1687","article-title":"Tracking cell transplants in femoral osteonecrosis with magnetic resonance imaging: A proof-of-concept study in patients","volume":"24","author":"Theruvath","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119846_bib47","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1148\/radiol.2018181204","article-title":"Quantification of Macrophages in High-Grade Gliomas by Using Ferumoxytol-enhanced MRI: A Pilot Study","volume":"290","author":"Iv","year":"2019","journal-title":"Radiology"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:02:40Z","timestamp":1790082160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226008826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":47,"alternative-id":["S0753332226008826"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119846","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor size limits macrophage activation and imaging response to CD47 blockade in osteosarcoma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119846","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119846"}}